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Patients with obstructive sleep apnea (OSA) frequently present with symptoms of depression and anx-
iety. The objective of this study is to determine if treatment with positive airway pressure (PAP) improves
symptoms of depression and anxiety. A systematic review was conducted to identify clinical trials of PAP
that contained a validated measure of depression severity. Meta-analysis was conducted for depression,
anxiety, excessive daytime sleepiness (EDS), quality of life (QoL) and respiratory variables. The systematic
review included 33 reports. Pre-post-test analysis of PAP showed a moderate effect size (Hedge's g, 95%
CI) for depression 0.524 [0.401e0.647], but a low effect size compared to oral placebo (0.355 [0.187
e0.524]) and no effect when compared to dental appliances (0.107 [0.72e0.287]) and sham PAP
(0.049 [0.292e0.194]). Anxiety, EDS, and QoL showed similar improvement in pre-post-test analysis,
but a lack of superiority to dental appliances and sham PAP. PAP was superior to all comparators for
respiratory variables. PAP has a moderate clinical effect on symptoms of depression and anxiety in OSA,
but it is not superior to dental appliances or sham PAP. The improvement in subjective symptoms, such
as depression and anxiety, may be mediated by patient expectations and contact with healthcare
providers.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Obstructive sleep apnea (OSA) is characterized by repetitive
sleep-related episodes of complete (apnea) or partial (hypopnea)
obstruction of the upper airwayor respiratoryeffort related arousals
(RERAs) [1,2]. Globally, OSA associated with daytime sleepiness is
reported to occur in 2%e5% of adultwomen and 3%e7% of adultmen
[1,2]. OSA is associated with multiple other medical comorbidities
including; hypertension, insulin-resistance, type II diabetes, and
obesity [2]. Positive airway pressure (PAP) delivered in continuous
(CPAP), bilevel (BiPAP) or autotitrating (APAP) modes is a standard
therapy for moderate (respiratory disturbance index (RDI) 15 and
30) to severe (RDI>30/hour) OSA and an optional therapy for mild
(RDI5and<15)OSA [3,4]. PAP is believed tobe effective in reducing
the apnea-hypopnea index (AHI) or RDI by providing pneumatic
splinting of the upper airwayduring sleep [3,5]. There is a large body
of evidence showing that PAP improves objective symptoms of OSA
including the AHI and blood pressure [6].ite 101 London, Ontario, N6J
Ltd. This is an open access article uThe presence of psychological symptoms in patients with OSA
hasbeen recognized since the1970s [7] and signiﬁcantevidence that
there are elevated levels of OSA in patients with clinical depression
has emerged since the early 2000s [8]. The recognition of the
importanceof depression inOSA is exempliﬁedby the fact that in the
most recent edition of the International classiﬁcation of sleep dis-
orders [ICSD3], diagnosis of amooddisorder (CriterionA.4) is among
one of the four major groups of symptoms (eg., excessive daytime
sleepiness, habitual snoring) or disorders (eg., hypertension, atrial
ﬁbrillation) that must be present along with 5 obstructive respi-
ratory events per hour, before an OSA diagnosis can be made.
The relationship between objectively-rated features of OSA and
symptoms like depression, anxiety, and excessive daytime sleepiness
(EDS) is poorly understood [8e10]. This constellation of symptoms is
often referred to as subjective symptoms of OSA, as there is typically
no consistent correlation between the severity of these symptoms
and the severity of OSAmeasuredbyobjectively-rated sleep variables
[11e17]. Current models for the relationship between OSA and psy-
chiatric conditions suggest that underlying biological, metabolic and
neurological dysregulation contributes to a feed-forwardmechanism
that manifests as psychiatric disorders, sleep fragmentation,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
AHI apnea hypopnea index
AI arousal index
APAP autotitrating positive airway pressure
BAI Beck anxiety inventory
BDI or BDI-II Beck depression inventory
BiPAP bilevel positive airway pressure
BSI-A brief symptom inventory e anxiety subscale
BSI-D brief symptom inventory e depression subscale
CES-D center for epidemiological studies depression scale
CONSORT consolidated standards of reporting trials
CPAP continuous positive airway pressure
DA dental appliance
EDS excessive daytime sleepiness
ESS Epworth sleepiness scale
FOSQ functional outcomes of sleep questionnaire
GHQ-28 general health questionnaire
GRADE grades of recommendation, assessment, development
and evaluation
HADS hospital anxiety and depression scale
HAM-D Hamilton rating scale for depression
ICSD3 International classiﬁcation of sleep disorders 3
ITT intention-to-treat
MADRS MontgomeryeÅsberg depression rating scale
Mean SaO2 mean oxygen saturation
Min SaO2minimum oxygen saturation
MMPI Minnesota multiphasic personality inventory
MSLT multiple sleep latency test
N/A not applicable
NHP-2 Nottingham health proﬁle-2
OP oral placebo
OSA obstructive sleep apnea
PAP positive airway pressure
POMS proﬁle of mood states
PRISMA preferred reporting items for systematic reviews and
meta-analyses
QoL quality of life
RCT-P parallel-group randomized controlled trial
RCT-X crossover randomized controlled trial
RDI respiratory disturbance index
REM% rapid eye movement sleep percentage
RoB risk of bias
SAQLI sleep apnea quality of life index
SAT single assignment trial
SDS Zung self rated depression scale
SF-36 short form health survey
SSS Stanford sleepiness scale
STAI state trait anxiety inventory
TAS tension anxiety scale
TEAE treatment emergent adverse event
WHO-5 World Health Organization-ﬁve well-being index
WHOQoL-B World Health Organization quality of life-brief
questionnaire (all subscales)
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tive symptoms of OSA are the result of complex biological dysregu-
lation, it remains unclear whether these symptoms have a direct
response to PAP therapy. Saunamaki et al. found that symptoms of
depression and anxiety were commonly reported in treatment naïve
OSA patients with multiple studies reporting improvements in these
symptoms after 3 mo of PAP [11]. Sanchez et al. also reported on
improvements in symptoms of EDS and mood in response to CPAP
therapy [18]. Both of these reviews reached their conclusions by
focusing on the number of studies reporting the positive effects of
PAP; this type of analysis is less accurate as it presents the overall
research in the ﬁeld by study outcome, whereas meta-analysis pools
participant data across studies to create a more accurate analysis of
the effects of PAP based on the total population studied [11,18]. A
recent meta-analysis concluded that treatment of OSA with PAP or
mandibular advancement devices is superior to placebo for the
treatment of depressive symptoms, but did not evaluate PAP vs.
active therapies [19]. The goal of this systematic review and meta-
analysis is to determine if PAP therapy improves depression and
other subjective symptoms inOSA in comparison to bothplacebo and
active treatments, as measured by validated rating scales.
Objective
The primary objective is to determine if treatment with PAP
improves the psychological symptoms of depression in patients
with OSA. The secondary objective was to evaluate if PAP improved
additional subjective sleep outcomes including: anxiety and EDS.
Methods
The methodology for this paper follows PROSPERO protocol
CRD42014007419 registered February 3, 2014 in accordance with
the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) statement [20,21].Eligibility criteria
Types of studies
This review considered single arm trials (SAT), case-control
trials, and randomized controlled trials (RCTs) of both parallel-
group and crossover design of PAP interventions for OSA.
Types of participants
Adult men and women with OSA diagnosed by poly-
somnography (PSG) were included. OSA was deﬁned as an AHI 5
(or RDI equivalent). Studies were only included when participants
were treatment naïve at study initiation. Studies where the primary
study sample involved individuals with severe or acute co-morbid
medical illness such as acute myocardial infarction, stroke, de-
mentia or heart failure were also excluded.
Types of interventions
Studies included PAP devices titrated to an effective pressure to
overcome the respiratory disturbance. The analyses include studies
with comparators consisting of healthy controls, sham or placebo
PAP groups or active comparator controlled studies. This analysis
also considered participant controlled pre- and post-intervention
data.
Types of outcome measures
The primary outcome measure for the meta-analysis was
depression. On this basis, all studies were required to include at
least one validated measure of depression such as the Beck
depression inventory (BDI), Montgomery-Asberg depression rating
scale (MADRS), hospital anxiety and depression scale (HADS), or
Hamilton depression scale (HAM-D).
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of life (QoL). This meta-analysis also evaluated the polysomno-
graphic (PSG) indices: AHI/RDI, mean oxygen saturation (Mean
SaO2), minimum oxygen saturation (Min SaO2), and arousal index
(AI). These outcomes were included as they have known physio-
logical efﬁcacy in OSA. As known objective outcomemeasures, they
can provide context for the subjective measures evaluated.
Additional outcome measures present in the studies were
included if they were identiﬁed during data extraction.
Information sources
Electronic searches
The Cochrane central register of controlled trials (CENTRAL) in
The Cochrane Library;
MEDLINE via OVID (from 1946);
EMBASE via OVID (from 1947);
PsycInfo via OVID (from 1806) and
Trials registers
ThemetaRegister of controlled trials (www.controlled-trials.com);
The US National Institutes of Health ongoing trials register
(www.clinicaltrials.gov);
The Australian New Zealand clinical trials registry (www.anzctr.
org.au);
The World Health Organization International clinical trials
registry platform (www.who.int/trialsearch);
The EU clinical trials register (www.clinicaltrialsregister.eu);
The Latin American and Caribbean health science information
database (http://lilacs.bvsalud.org/en/).
Search
The search strategies for all databases are included in
Supplement 1. The reference lists of all primary studies and review
articles were checked for additional references.
Study selection
Studies were screened for relevance to the topic by title, fol-
lowed by abstract and/or full text article. Articles were screened for
inclusion by two reviewers (FS and DL). Studies that were not in
English or conducted using animals were excluded.
Data collection process
Data extraction was performed by two independent reviewers
(FS and DL) using data collection forms. The data forms were
piloted before use and included: Study identiﬁer, study design,
number of participants per group, baseline characteristics, inter-
vention, treatment regimen and duration, treatment success and
failure, efﬁcacy, safety, morbidity and mortality, tolerability,
compliance, number of patients lost to follow-up, and the duration
of follow-up. Disagreements were resolved with discussion, or if
agreement could not be reached, a third author (MAG) assisted in
the resolution of any discrepancies. The data were entered by a
single author (FS) and veriﬁed by both reviewers (FS and DL). Data
were entered as intention-to-treat (ITT) data, and per protocol re-
sults was converted into ITT data wherever possible to reduce bias.
Risk of bias in individual studies
The risk of bias (RoB) in individual studies was evaluated using
the Cochrane risk of bias tool in RevMan version 5.2 (Copenhagen,
Denmark) [22,23].Measures of treatment effect
Treatment effect was assessed bymeta-analysis if therewere2
studies that assessed the outcome measure. Effect size was pre-
sented using Hedges' g for continuous measures and odds ratios
(OR) for binary data [22,24]. If there was insufﬁcient evidence for
meta-analysis, the study outcomes were described verbally, and
not included in the meta-analysis.
Unit of analysis issues
The unit of analysis reported was the participant. In cross-over
study designs, participant controlled data were used wherever
possible or the ﬁrst intervention period was used where
participant-controlled data were unavailable. If studies reported
more than one outcome measure included in this review, all of the
outcomes were included in the analyses.
Dealing with missing data
Principal investigators and/or study sponsors were contacted to
obtain missing data and verify any unclear study parameters.
Where this was not possible, and the missing data was felt to
introduce a serious bias, sensitivity analysis was conducted to
explore the impact of the missing data.
Assessment of heterogeneity
The I2 statistic was used to measure the proportion of variance
attributable to heterogeneity among the trials in each analysis
[22,24]. Where substantial heterogeneity was identiﬁed, it was
reported and possible causes were explored by pre-speciﬁed sub-
group analysis. Heterogeneity was stratiﬁed into I2 values for low
(25%), medium (50%) and high (>75%) heterogeneity [24].
Assessment of reporting biases
Analyses containing10studieswereassessed forpublicationbias
using funnel plots and Duval and Tweedie's trim and ﬁllmethod [24].
Data synthesis
All meta-analyses were conducted with a pre-speciﬁed random-
effects model to account for heterogeneous treatment effects and
varying true effect sizes across studies. Meta-analyses were
required to have an I2 value 75% for inclusion. Where more than
one scale was used to assess an outcome measure (i.e., depression
by BDI and HADS), the mean of the outcomes was used. Pre-post
test analysis used the PAP arm of SATs, parallel RCTs, and cross-
over RCTs where pre- and post-test data were presented. The an-
alyses for RCTs used both parallel and crossover designs, where the
crossover trials presented participant controlled data. The meta-
analysis calculations were performed using Comprehensive Meta-
Analysis Version 2.2.064 (Englewood, NJ) [25].
Risk of bias across studies
The RoB across studies was evaluated for each meta-analysis
using grades of recommendation, assessment, development and
evaluation (GRADE) and GRADEpro software [22,26].
Subgroup analysis and meta-regression
Prospective subgroup and meta-regression analysis were
intended to be conducted by gender, OSA severity (AHI/RDI), body
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severity based on the heterogeneity of the results. However, as all of
the pre-speciﬁed analyses had heterogeneity below 50%, these
analyses were not included in the ﬁnal manuscript.
Results
Description of studies
Results of search
The results of the search strategy can be found in Fig. 1. The
search was completed on June 20, 2014. Thirty-three reports of 31
studies met the inclusion criteria for this review (Supplement,
Table S2) [27e59].
Included Studies
A list of the included studies can be found in Table S2. The
characteristics of the included studies are summarized in Table 1.
Study design
The included studies are comprised of single assignment trials,
randomized trials, and current or future study protocols (Table 1).
Fig. 1 shows the number of each class of trial identiﬁed. Of the
randomized studies, four were parallel assignment studies
[42,45,46,52,59] and six were crossover trials [28,37e40,47].Fig. 1. Flow diagram of systematic review. The systematic review resulted in 33 reports of 3
combined under a single study identiﬁer to prevent duplication.Participants
The included studies enrolled a total of 895 participants. Seven
studies enrolled fewer than 20 participants [33,34,39,48,50,52,58],
and two studies enrolled more than 100 participants [28,44].
Participant mean BMI ranged from 27.8 to 38 kg/m2 where recor-
ded, indicating that the participants ranged from overweight to
obese [34,52,58]. Participant mean baseline AHI ranged from 11.0 to
71.5 per hour where reported, including a full spectrum of mild to
severe OSA [39,48].
Interventions
A total of seven interventions were measured in the included
studies. All of the studies evaluated CPAP devices. In addition to the
required PAP treatment, the completed studies included oral pla-
cebo [28,37e40], oral/dental appliances [28,52], exercise [52], and
sham PAP [42,45e47,59]. Two trial protocols also included gastric
bypass surgery and lifestyle/behavioural modiﬁcation as arms of
parallel-assignment trials [30,31]. The studies ranged in duration
from 11 d to two y [57,59].
Outcomes
The included studies reported a diverse array of psychological
and physiological outcomemeasures (Table 2). EDS was reported as
an outcome measure for 18 completed trials
[28,32,33,35e41,43,44,47,48,52e54,57,58] and ﬁve trial protocols1 studies. In cases where there were multiple records of a study population, they were
Table 1
Summary of included studies.
Study Trial type Intervention Control ITT
sample
Study
duration
Psychiatric
scales
EDS scale QoL scale Age
(mean ± SD)
Male (%) BMI
(kg/m2,
mean ± SD)
AHI/RDI
(events/h,
mean ± SD)
AFIP 2014 [27] Protocol CPAP Oral appliance 90* 3 y BDI, BAI ESS e N/A N/A N/A N/A
Barnes 2004 [28] RCT-X CPAP Dental appliance or oral placebo 114 3 mo BDI, POMS ESS, SSS SF-36 47 ± 0.9 80% 31.1 ± 0.5 21.3 ± 1.3
Borak 1996 [29] SAT CPAP e 20 12 mo BDI, TAS e e 46 ± 6 e e 67 ± 16
BWH 2014 [30] Protocol CPAP Gastric bypass surgery 80* 9 mo PHQ-9 ESS GQL N/A N/A N/A N/A
Campos-Rodriguez 2014 [31] Protocol CPAP Dietary and lifestyle advice 300* 12 wk POMS, HADS ESS SF-12, N/A N/A N/A N/A
Castronovo 2009 [32,33] SAT CPAP e 14 4 mo BDI ESS SF-36 43.93 ± 7.8 100% 30.29 ± 4.8 50.14 ± 24.8
Derderian 1988 [34] SAT CPAP e 7 2 mo POMS e e 59.3 ± 5.8 100% 27.8 ± 2.4 e
Diamanti 2013 [35] SAT CPAP e 24 8 mo CES-D QSQ WHOQoL 51.88 ± 10.6 83% 34.37 ± 6.5 37.5 ± 6.45
El-Sherbini 2011 [36] SAT CPAP e 37 3 mo HAM-D ESS e 44.9 ± 8.8 65% e 27.7 ± 7.3
Englemann 1994 [38] RCT-X CPAP Oral placebo 32 4 wk HADS ESS NHP-2 49 ± 8.4 81% 33 ± 1.6 28
Englemann 1997 [39] RCT-X CPAP Oral placebo 16 4 wk HADS ESS GHQ-28, NHP-2 52 ± 7.7 75% 29.8 ± 7 11 ± 3.9
Englemann 1998 [40] RCT-X CPAP Oral placebo 23 4 wk HADS ESS GHQ-28, NHP-2 47 ± 12 91% 30 ± 7 43 ± 37
Englemann 1999 [37] RCT-X CPAP Oral placebo 34 4 wk HADS ESS SF-36, NHP-2 44 ± 8 62% 30 ± 5 24 ± 10
Ferini-Strambi 2003 [41] SAT CPAP e 23 6 mo BDI ESS e 56.52 ± 6.1 91% 33.45 ± 5.6 55 ± 13.4
Haensel 2007 [42] RCT-P CPAP Sham CPAP 25/25 14 d POMS e e 48.2 ± 10.2 80% 33.1 ± 8.2 63.6 ± 29.1
Herold 2011 [43] SAT CPAP e 60 6 mo BDI,
HAM-D, MADRS
ESS, PSQI WHO-5 54.77 ± 10 38% e 30 ± 21.9
Kawahara 2005 [44] SAT CPAP e 132 56 d SDS ESS e 48.8 ± 11.9 94% 28.3 ± 4.3 59.4 ± 23.8
Lee 2012 [45,46] RCT-P CPAP Sham CPAP 26/30 21 d BSI, CES-D, POMS e e 46 ± 9.4 84% 29.2 ± 4.2 33.9 ± 20.1
Marshall 2005 [47] RCT-X CPAP Sham CPAP 31 8 wk HADS ESS FOSQ, SF-36 50.5 [25e67] 76% 31.5 ± 6.0 21.6 ± 7.5
O'Donoghue 2012 [48] SAT CPAP e 30 6 mo BDI ESS FOSQ 45.2 ± 9.6 100% 33.3 ± 4.6 71.5 ± 16.2
Paparigopoulos 2009 [49] SAT CPAP 56 1 mo HADS e SF-36 47.4 ± 8.1 93% 31 ± 5.7 54.5 ± 27.4
Ramos Platon 1992 [50] SAT CPAP e 23 11 mo MMPI e e 53.3 ± 10.7 97% e e
Sanchez 2001 [51] SAT CPAP 51 3 mo BDI, STAI e e 48.04 ± 8.6 88% e 61.32 ± 21.9
Schutz 2013 [52] RCT-P CPAP Dental appliance or exercise 9/9/7 60 d POMS ESS SF-36 41.1 ± 7.5 e 27.8 ± 3.5 26.2 ± 14.7
Schwartz 2005 [54] SAT CPAP e 50 4-6 wk BDI ESS e 48.4 ± 9.3 66% 37 ± 8.6 55.8 ± 34.4y
Schwartz 2007 [53] SAT CPAP e 50 600 d BDI ESS e 53 ± 11.3 78% 35 ± 7.7 57.4 ± 31.1y
Stanford 2014 [55] Protocol CPAP Oral appliance 238* 6-9 mo POMS FOSQ, SAQLI SF-36 N/A N/A N/A N/A
Uppsala 2014 [56] Protocol CPAP Physical activity to promote
weight loss
140* 18 mo MADRS ESS SF-36 N/A N/A N/A N/A
Yamamoto 2000 [57] SAT CPAP e 46 2 y SDS ESS e 49.5 ± 10.8 100% 29.2 ± 5.4 e
Ye 2009 [58] SAT CPAP e 176 3 mo POMS ESS, FOSQ, MSLT e 46.7 ± 8.8 86% 38 ± 8.2 63.9 ± 29.4
Yu 1999 [59] RCT-P CPAP Sham CPAP 20/14 11 d POMS e e 48.2 ± 8.9 74% e 40.55 ± 23.6y
() not reported, (*) Planned enrollment, (y) RDI - respiratory disturbance index, N/A e not applicable, AHI e apnea hypopnea index, BAI e Beck anxiety inventory, BDI e Beck depression inventory, CPAP e continuous positive
airway pressure, CES-D e Center for epidemiological studies depression scale, ESS e Epworth sleepiness scale, FOSQ e functional outcomes of sleep questionnaire, GHQ-28 e general health questionnaire, HADS e hospital
anxiety and depression scale, HAM-D e Hamilton rating scale for depression, ITT e intention-to-treat, MADRS e Montgomery-Åsberg depression rating scale, MMPI e Minnesota multiphasic personality inventory, MSLT e
multiple sleep latency test, POMS e proﬁle of mood states, RCT-P e parallel-group randomized controlled trial, RCT-X e crossover randomized controlled trial, SAQLI e sleep apnea quality of life index, SAT e single assignment
trial, SDS e Zung self-rated depression scale, SSS e Stanford sleepiness scale.
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Table 2
Outcome measures.
Outcome measure Scales assessed
Depression BDI or BDI-II e Beck depression inventory, BSI-D e brief symptom inventory e depression subscale, CES-D e Center for epidemiological studies
depression scale, HADS-D e hospital anxiety and depression scale e depression subscale, HAM-D e Hamilton rating scale for depression,
MADRS e Montgomery-Åsberg depression dating scale, MMPI e Minnesota multiphasic personality inventory e depression subscale,
POMS-D e proﬁle of mood states e depression subscale, SDS e Zung self-rated depression scale
Excessive daytime
sleepiness (EDS)
ESS e Epworth sleepiness scale, QSQ- Quebec sleepiness questionnaire , SSS e Stanford sleepiness scale
Anxiety BSI-A e brief symptom inventory e anxiety subscale, HADS-A e hospital anxiety and depression scale e anxiety subscale, MMPI-Pt e Minnesota
multiphasic personality inventory- psychasthenia subscale, POMS-T e proﬁle of mood states -tension and anxiety subscale, STAI e state trait
anxiety inventory, TAS e tension anxiety scale
Quality of life (QoL) GHQ-28 e general health questionnaire, NHP-2 e Nottingham health proﬁle-2, SF-36 - short form health survey (all subscales),
WHO-5 eWHO-ﬁve well-being index , WHOQoL-B eWorld Health Organization auality of life-brief questionnaire (all subscales)
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15 completed trials [28,29,34,37e40,42,45e47,49,50,52,58,59] and
three trial protocols [27,31,55]. QoL was reported by eight
completed trials [28,32,33,35,37,39,40,43,47,49,52] and four trial
protocols [30,31,55,56].
Funding
Thirteen of the included studies had no identiﬁable source of
funding [34e36,38,41,43,44,49e51,53,54,57]. Twelve of the studies
received funding from government grants or charitable organiza-
tions [28,29,31e33,37,40,42,45e47,52,58,59]. Four studies received
equipment or drugs from commercial interests [28,39,48,58].
Excluded studies
There were 46 studies excluded from the full text search
(Table S3). The primary reason for exclusion was an inability to
extract data from studies that otherwise met the inclusion criteria,
when contacting the authors failed (Table S4). The secondary rea-
sons were lack of a psychiatric scale and OSA diagnoses reported
without PSG results (Table S4).
Risk of bias in included studies
Allocation
The studies identiﬁed in this systematic review were primarily
single-assignment prospective trials or retrospective reviews. Of
the 10 completed randomized controlled studies, two had adequate
randomization procedures (Fig. 2) [37,45]. Allocation concealment
was only possible in the four sham controlled PAP studies. The
method of concealment was not described in three of these studies
[42,45,59] and in the fourth study participants were informed that
the trial was for two different pressures of humidiﬁed PAP [47].
Blinding
The blinding of studies in this systematic review was subject to
either unclear or high risk of bias (Fig. 2). The single-assignment
trials largely do not discuss blinding and are presumably open la-
bel trials. Of the 10 randomized controlled trials, ﬁve are crossover
studies of mixed treatments which cannot be participant-blinded
[28,37e40], one is a crossover of PAP and sham PAP which does
not report blinding [47], and two of these are open-label trials
without evaluator blinding [38,40]. Of the ﬁve parallel group
studies, two had adequate blinding of participants and evaluators
[45e47], while the other three had unclear blinding procedures
[42,52,59].
Incomplete outcome data
Incomplete outcome data were absent in the majority of
completed studies (Fig. 2). There was a low risk of bias for incom-
plete outcome data in 20 studies. Unclear outcome data werepresent in two studies [29,49]. There was a high risk of bias for
incomplete outcome data in three studies [44,54,59].
Effect of interventions
The magnitude of change caused by the interventions is pre-
sented as effect size measured as Hedge's g. The interpretation of
these effect sizes requires context to determine how the statistical
effect size corresponds to the magnitude of clinical change
observed. Based on the range of effect sizes presented in this
analysis and their correlations to known objective measures of the
effects of PAP on sleep symptoms such as AHI [6], effect sizes will be
interpreted as <0.5 low, 0.5e1.0 moderate and >1.0 as high.
PAP pre-post intervention
Twenty-one of the included studies assessed the change in
depression and other outcome measures pre- and post-PAP treat-
ment (Table 3) [28,29,33e37,40e44,47e52,54,57,59]. Comparison
of participants who underwent PAP therapy at baseline and follow-
up shows positive effect sizes for all outcome measures post-
treatment (Table 3). These analyses are subject to an overall high
RoBwith a GRADE evaluation of ‘very low’ for all outcomemeasures
other than AHI/RDI which was ‘low’. The effect size for the primary
outcome measure of depressive symptoms was 0.524
[0.401e0.647], which corresponds to a moderate clinical effect
(Fig. 3A). A high effect size was observed for symptoms of EDS
(1.015 [0.697e1.333]) (Fig. 3C). The secondary outcomemeasures of
anxiety (0.413 [0.263e0.563], Fig. 3B) and QoL (0.435
[0.236e0.634], Fig. 3D) had low effect sizes. The FOSQ has a mod-
erate outcome (0.509 [0.219e0.799], Figure S1D). The objective
sleep measure AHI/RDI had a large effect size (1.479 [1.277e1.680])
(Figure S1A). The AI (0.624 [0.137e1.384], Figure S1C) and mean
SaO2 (0.972 [0.159e2.104], Figure S1B) also showed moderate
effect sizes, but the 95% CI indicates that these are not clinically
signiﬁcant.
PAP versus oral placebo
Comparisons of PAP with oral placebo were conducted in ﬁve of
the included studies (Table 4, Fig. 4) [28,37e40]. All of the analyses
indicate that PAP is more effective than oral placebo (Table 4, Fig. 4
and S2). These analyses are subject to an overall high RoB with a
GRADE evaluation of ‘low’ for all outcomemeasures other than EDS
which was ‘moderate’. The primary outcome measure for depres-
sion showed a low effect size of 0.355 [0.187e0.524] (Fig. 4A). The
change in EDS was moderate with an effect size of 0.608
[0.090e1.126] (Fig. 4C). Anxiety (0.225 [0.093e0.357], Fig. 4B) and
QoL (0.491 [0.126e0.855], Fig. 4D) had low effect sizes favoring PAP.
The meta-analysis for QoL had moderate heterogeneity of 33.96%
which is larger than the heterogeneity observed for the other an-
alyses in this comparison. The moderate QoL heterogeneity
Fig. 2. Individual RoB for the included studies. (þ) low risk of bias, (?) unclear risk of
bias, () high risk of bias.
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QoL scales that were utilized.
PAP versus dental appliances
Two studies compared PAP and dental appliances (Table 5, Fig. 5
and S2) [28,52]. The RoB for both studies was ‘low’. The comparison
between PAP and dental appliances did not show a signiﬁcant
difference between the two treatments for depression (0.107
[0.72e0.287], Fig. 5A), EDS (0.058 [0.121e0.237], Fig. 5C) or QoL
(0.021 [0.157e0.200], Fig. 5D). Therewas a low effect size favoring
PAP for anxiety 0.101 [0.078e0.280] (Fig. 5B). The effect size for
AHI/RDI favored PAP over dental appliances with a moderate effect
size of 0.902 [0.692e1.113] (Figure S2A). There was also a low effect
size of 0.473 [0.285e0.661] favoring PAP for improvements in AI
(Figure S2B).
PAP versus sham PAP
Four studies compared PAP to sham PAP (Table 6, Fig. 6 and S4)
[42,45e47,59]. The analyses for depression, anxiety and mean SaO2
received ‘low’ GRADE assessment scores, while the AHI/RDI anal-
ysis received a ‘high’ GRADE assessment. The effect sizes for
depression (0.049 [0.292e0.194], Fig. 6A) and anxiety (0.073
[0.315e0.169], Fig. 6B) show that PAP is not more effective than
sham PAP at reducing psychological symptoms. There was a high
effect size for AHI/RDI in favor of PAP 1.881 [1.370e2.391]
(Figure S3A). The effect size for mean SaO2 was 0.575
[0.420e1.570] (Figure S3B), but the large 95% CI indicates that this
result has too much variance to be considered clinically relevant.
EDS and QoL were not assessed in the PAP vs. sham PAP studies.
PAP vs. exercise
One study evaluated PAP vs. exercise for the treatment of OSA
[52]. Meta-analysis was not possible; however, this study did
measure the difference in depression, EDS, anxiety, QoL and AHI. All
of the effect sizes favored PAP over exercise. Depression and anxiety
were measured using the proﬁle of mood states (POMS) scale. The
effect size for POMS-depression was low at 0.094 ± 0.477 (Hedge's
g ± SE) and the effect size for POMS-tension and anxiety was also
low at 0.349 ± 0.480. EDS was measured by the Epworth sleepiness
scale (ESS) with a moderate effect size of 0.709 ± 0.493. The effect
sizes for respiratory variables were both large with 2.007 ± 0.594
for AHI and 1.033 ± 0.510 for AI. The effect size for the SF-36 mean
score was also large at 1.225 ± 0.523.
Discussion
Summary of main results
Our systematic review identiﬁed 31 studies pertaining to the
effects of PAP on depressive symptoms in individuals with OSA. Of
the included studies, 26 were completed trials and ﬁve were trial
protocols that are currently active or enrolling participants. The
majority of studies were single-assignment prospective trials or
retrospective reviews. The results of this meta-analysis show that
PAP had amoderate impact on symptoms of depression and anxiety
when the psychological measures were carried out pre-to post-PAP.
PAP had low impact on symptoms of depression and anxiety when
compared with oral placebo, but was not more effective at reducing
depression and anxiety than sham PAP or dental appliances. In
contrast, PAP was consistently more effective than placebo, sham
PAP or dental appliances in decreasing the AHI.
This review conﬁrms that the relationship between depression,
anxiety, EDS and OSA is complex. The contrast between subjective
and objective symptoms is underscored by the fact that PAP is
consistently more effective than placebo and active treatment
Table 3
Pre-versus Post-PAP.
Outcome measure No. of studies No. of participants Statistical method Effect size Heterogeneity (I2) GRADE assessment
Depression 21 803 Hedge's g (Random, 95% CI) 0.524 [0.401e0.647] 4.24% Very low
Anxiety 12 406 Hedge's g (Random, 95% CI) 0.413 [0.263e0.563] 3.62% Very low
EDS 16 832 Hedge's g (Random, 95% CI) 1.015 [0.697e1.333] 0% Very low
QoL 9 365 Hedge's g (Random, 95% CI) 0.435 [0.236e0.634] 4.32% Very low
AHI/RDI 6 278 Hedge's g (Random, 95% CI) 1.479 [1.277e1.680] 5.54% Low
Mean SaO2 3 52 Hedge's g (Random, 95% CI) 0.972 [0.159e2.104] 0% Very low
AI 2 123 Hedge's g (Random, 95% CI) 0.624 [0.137e1.384] 0% Very low
FOSQ 4 334 Hedge's g (Random, 95% CI) 0.509 [0.219e0.799] 49.89% Very low
AHI e apnea hypopnea index, AI - arousal index, EDS - excessive daytime sleepiness, FOSQ - functional outcomes of sleep questionnaire, GRADE - grades of recommendation,
assessment, development and evaluation, mean SaO2 e mean oxygen saturation, QoL e quality of life, RDI - respiratory disturbance index.
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RDI, AI, and mean SaO2. It has previously been hypothesized that
OSA, psychological symptoms, and metabolic disease are the
diverse consequences of underlying biological, metabolic and
neurologic dysregulation [8e10]. Psychiatric, sleep and metabolic
disorders can each be the primary manifestation and entry point
into a feed-forward mechanism where underlying inﬂammation,
oxidative and nitrosative stress, and neurotransmitter imbalances
increase the likelihood of the individual expressing multiple dis-
ease states related to the underlying biological dysregulation [8]. In
some individuals, the development of OSA and resultant sleep
fragmentation may unmask an underlying predisposition for
depressive disorders. The application of PAP is unlikely to resolve
these problems directly, as PAP can only directly treat the respira-
tory symptoms that are an outcome of a complex process.
Improvement in AHI that is dependant solely on PAP, without other
autonomic and metabolic changes, may not be sufﬁcient to be
associated with a clinically signiﬁcant improvement in depression,
anxiety and EDS scores. The improvements in these symptoms may
derive from decreased arousals and hypoxemia or the long-term
positive impact of PAP on metabolic function [60,61]. Alterna-
tively, the improvement in depressive symptoms in pre-post-test
analysis and in comparison to oral placebo may be the result of
patient expectations, mediated primarily by interaction with the
healthcare system and reassurances of improvement in the par-
ticipant's condition [62]. Many of the included studies occur over
prolonged durations >90 d, where this interaction may have a
signiﬁcant impact.
Overall completeness and applicability of evidence
The evidence for the efﬁcacy of OSA in alleviating symptoms of
depression is largely incomplete. The duration of the studies ranged
from 11 d to 2 y (Table 1) and this is likely an important con-
founding factor in the improvement of a complex syndrome like
depression after treatment of the respiratory component of OSA
with PAP therapy. The lack of signiﬁcant heterogeneity in the an-
alyses suggests that time was not a signiﬁcant factor in these an-
alyses. One possible reason for the lack of an impact is that PAP is
predominantly a symptomatic treatment that is only effective
when being used, so the length of treatment is not a signiﬁcant
factor, despite known improvements in cardiovascular and endo-
crine function with PAP [6,60,61].
A second concern is the lack of RCTs assessing the effects of PAP
in comparison to dental appliances, sham PAP and exercise. While
there is an abundance of low quality evidence for the effect of PAP
pre- and post-treatment, there is insufﬁcient evidence for the
assessment of the outcomes of PAP vs. placebo and active com-
parators. The highest volume of data exists for the comparison of
PAP vs. oral placebo, but this is likely the least convincing placebo
arm for participants, despite instructions to the contrary. The evi-
dence for comparing PAP to dental appliances for psychologicalsymptoms is sparse, as is the evidence for PAP vs. sham PAP which
is the gold standard control.
An additional problemwith the completeness of this evidence is
the lack of dichotomous outcomes for clinical depression and
anxiety. This meta-analysis exclusively uses continuous outcome
measures of varying levels of psychological symptom severity. The
combination of multiple scales measuring the same psychometric
properties, but on different numerical scales, prevents us from
conducting meta-regression to determine if baseline severity has
an effect on the magnitude of change in depression. It would be
valuable to have data organized to give the proportion of partici-
pants meeting the severity criteria for clinical depression before
and after PAP to see if these proportions change. It would also be
valuable to be able to perform subgroup analysis on continuous
outcomes within participants grouped by severity.
Quality of the evidence
The quality of the evidence included in this review and meta-
analysis is low overall, reﬂecting the fact that the bulk of the data
was published before the widespread adoption of the consolidated
standards of reporting trials (CONSORT) statement, which is based
on the two-group parallel design [63]. The GRADE assessments for
the meta-analyses performed in this review were predominantly
‘very low’. The decision to evaluate single-arm trials of PAP was
based largely on the lack of availability of randomized controlled
trials; however, the quality of the evidence based upon single-arm
trials should be taken into consideration when interpreting the
clinical efﬁcacy indicated by the results. It is particularly telling that
the effect size for the primary outcome measure of depression di-
minishes as the methodological quality of the RCTs comparator arm
improves. This effect can be underscored by the fact that the effect
size for depression is null 0.049 [0.292e0.194] when PAP is
compared to sham PAP, but the effect size for change in AHI/RDI for
this comparison is the largest effect size 1.881 [1.370e2.391] re-
ported in the analysis.
Limitations
This meta-analysis includes single-assignment and random-
ized clinical trials with both parallel group and cross-over designs,
but there are more SATs than RCTs present in the analysis. A
similar meta-analysis published assessing mandibular advance-
ment devices or PAP in comparison to placebo focused solely on
RCTs [19]. There are advantages to pre-post PAP analysis, but the
low RoB associated with SATs cannot be overlooked. The other
limitation of this meta-analysis is the use of multiple scales to
measure the same psychometric variable [19]. The use of Hedge's
g should help to account for variability in the scale ranges, but this
is predicated on each scale having equivalent ability to measure
the same underlying construct, which may not be true in all cases.
The ratings of depression were primarily participant-rated and
Fig. 3. Pre-post PAP Forest plots. A) Depression, B) Anxiety, C) EDS, D) QoL. BDI e Beck depression inventory, CES-D e Center for epidemiological studies depression scale, EDS -
excessive daytime sleepiness, ESS e Epworth sleepiness scale, HADS-A e hospital anxiety and depression scale e anxiety subscale, HADS-D e hospital anxiety and depression scale
e depression subscale, HAM-D e Hamilton rating scale for depression, MMPI e Minnesota multiphasic personality inventory e depression subscale, MMPI-Pt e Minnesota
multiphasic personality inventory- psychasthenia subscale, PAP e positive airway pressure, POMS-D e proﬁle of mood states e depression subscale, POMS-T e proﬁle of mood
states -tension and anxiety subscale, QoL - quality of life, QSQ-DS - Quebec sleepiness questionnaire e daytime sleepiness, SDS e Zung self-rated depression scale, SF-36 - short form
health survey (all subscales), WHO-5 - WHO-ﬁve well-being index.
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Table 4
PAP versus oral placebo.
Outcome measure No. of studies No. of participants Statistical method Effect size Heterogeneity (I2) GRADE assessment
Depression 5 219 Hedge's g (Random, 95% CI) 0.355 [0.187e0.524] 0.29% Low
Anxiety 5 219 Hedge's g (Random, 95% CI) 0.225 [0.093e0.357] 0% Low
EDS 4 187 Hedge's g (Random, 95% CI) 0.608 [0.090e1.126] 0% Moderate
QoL 5 219 Hedge's g (Random, 95% CI) 0.491 [0.126e0.855] 33.95% Low
AHI/RDI 1 114 Hedge's g (Random, 95% CI) e e e
AI 1 114 Hedge's g (Random, 95% CI) e e e
AHI e apnea hypopnea index, AI - arousal index, EDS e excessive daytime sleepiness, GRADE - grades of recommendation, assessment, development and evaluation, QoL e
quality of life, RDI - respiratory disturbance index.
Fig. 4. PAP vs. oral placebo Forest plots. A) Depression, B) Anxiety, C) EDS, D) QoL. EDS e excessive daytime sleepiness, ESS e Epworth sleepiness scale, HADS-A e hospital anxiety
and depression scale e anxiety subscale, HADS-D e hospital anxiety and depression scale e depression subscale, OP e oral placebo, PAP e positive airway pressure, POMS-T e
proﬁle of mood states -tension and anxiety subscale, QoL e quality of life, SF-36 - short form health survey (all subscales).
Table 5
PAP versus dental appliance.
Outcome measure No. of studies No. of participants Statistical method Effect size Heterogeneity (I2) GRADE assessment
Depression 2 132 Hedge's g (Random, 95% CI) 0.107 [0.72e0.287] 0% Low
Anxiety 2 132 Hedge's g (Random, 95% CI) 0.101 [0.078e0.280] 0% Low
EDS 2 132 Hedge's g (Random, 95% CI) 0.058 [0.121e0.237] 0% Low
QoL 2 132 Hedge's g (Random, 95% CI) 0.021 [0.157e0.200] 0% Low
AHI/RDI 2 132 Hedge's g (Random, 95% CI) 0.902 [0.692e1.113] 0% Low
AI 2 132 Hedge's g (Random, 95% CI) 0.473 [0.285e0.661] 0% Low
FOSQ 1 114 Hedge's g (Random, 95% CI) e e e
AHIe apnea hypopnea index, AI - arousal index, FOSQe functional outcomes of sleep questionnaire, EDSe excessive daytime sleepiness, GRADE - grades of recommendation,
assessment, development and evaluation, QoL e quality of life, RDI - respiratory disturbance index.
Fig. 5. PAP vs. dental appliances Forest plots. A) Depression, B) Anxiety, C) EDS, D) QoL. DA e dental appliance, EDS e excessive daytime sleepiness, ESS e Epworth sleepiness scale,
PAP e positive airway pressure, POMS-D e proﬁle of mood states e depression subscale, POMS-T e proﬁle of mood states -tension and anxiety subscale, QoL e quality of life, SF-36 -
short form health survey (all subscales).
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Table 6
PAP versus sham CPAP.
Outcome measure No. of studies No. of participants Statistical method Effect size Heterogeneity (I2) GRADE assessment
Depression 4 169 Hedge's g (Random, 95% CI) 0.049 [0.292e0.194] 0% Low
Anxiety 4 169 Hedge's g (Random, 95% CI) 0.073 [0.315e0.169] 0% Low
EDS 1 31 Hedge's g (Random, 95% CI) e e e
QoL 1 31 Hedge's g (Random, 95% CI) e e e
AHI/RDI 2 84 Hedge's g (Random, 95% CI) 1.881 [1.370e2.391] 0% High
Mean SaO2 2 39 Hedge's g (Random, 95% CI) 0.575 [0.420e1.570] 0% Low
AI e e Hedge's g (Random, 95% CI) e e e
FOSQ 1 31 Hedge's g (Random, 95% CI) e e e
AHI e apnea hypopnea index, AI - arousal index, EDS - excessive daytime sleepiness, FOSQ - functional outcomes of sleep questionnaire, GRADE - grades of recommendation,
assessment, development and evaluation, mean SaO2 e mean oxygen saturation, QoL e quality of life, RDI - respiratory disturbance index.
Fig. 6. PAP vs. sham CPAP Forest plots. A) Depression, B) Anxiety. CPAP e continuous positive airway pressure, HADS-A e hospital anxiety and depression scale e anxiety subscale,
HADS-D e hospital anxiety and depression scale e depression subscale, PAP e positive airway pressure, POMS-D e proﬁle of mood states e depression subscale, POMS-T e proﬁle of
mood states -tension and anxiety subscale.
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ment of AHI by PSG. The decision to only include validated psy-
chometric scales in this analysis, without commonly accepted
substitutes such as the SF-36 mental health subscale, should
hopefully also help to combat this issue. This meta-analysis was
also conducted using individual comparisons between each pla-
cebo and active comparator control and PAP. This means that oral
placebo and sham PAP were assessed independently, rather than
as pooled placebo groups, where another meta-analysis has
distinguished between parallel and cross-over studymethodology
[19]. The participants in the oral placebo trials were participants
in crossover trials where the distinction between PAP and the oral
treatment received would be apparent to the participants,
whereas the participants in the sham PAP trials were more
effectively blinded to the trial arms.
This meta-analysis was also unable to assess the impact of se-
vere baseline depression versus subclinical depression. The studies
used by Povitz et al. to assess severe baseline depressive symptoms
were excluded from our analysis as one used the SF-36 mental
health subscale and the other was conducted in stroke patients
[19]. It would have been advantageous to compare the effect insevere and mild depression, as these populations are likely to have
different subjective responses to PAP.
Conclusions
The effect of PAP on symptoms of depression and anxiety, EDS
and QoL in patients with OSA was moderate. PAP was superior to
oral placebo, but not to sham PAP in RCTs for depression and
anxiety. PAP was also equivalent to dental appliances as a thera-
peutic option for improving subjective symptoms of depression and
anxiety. PAP had a signiﬁcant effect on the improvement of EDS
which moderately favored PAP over oral placebo, but was equiva-
lent to dental appliances. PAP was superior to all comparators for
improvement in AHI, AI, and mean SaO2. The relationship between
improvement in subjective symptoms of OSA and PAP is compli-
cated by the low overall quality of the evidence. Future randomized
controlled trials between PAP and sham devices or dental appli-
ances will be needed to determine if the effects of PAP are speciﬁc
to improvements in respiratory variables, or subjective improve-
ments due to the placebo effect of interaction with healthcare
providers.
Practice points
 PAP improves depressive symptoms in patients with
OSA, but it is not superior to dental appliances or sham
PAP.
 The beneficial effect of PAP may be greater in patients
with higher depression severity scores.
 If symptoms of depression do not improve after PAP
therapy with improvement of AHI, the depressive symp-
toms will need to be treated using standard psychiatric
therapies while the patient's OSA symptoms are being
monitored.
Research agenda
 Randomized controlled trials should be conducted
comparing the efficacy of PAP and sham PAP or active
therapy in participants with clinical depression versus
patients with subthreshold severity scores to determine
the relative efficacy of PAP in these populations.
 Outcomemeasures such as depression, anxiety, EDS and
quality of life should be included in all future trials of PAP
in comparison to active and sham control arms for OSA.
 Study of the correlation between baseline AHI and
response of subjective symptoms of depression and
anxiety to PAP may help to clarify the link between dis-
ease severity and subjective patient outcomes.
 Future RCTs should consider evaluating treatment by
time effects to determine the significance of length of
treatment in the improvement in subjective symptoms of
OSA such as depression.
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